KalVista – Talk Bio

Actionable Insights Powered by AI

FDA Delays Decision on KalVista’s HAE Drug Sebetralstat, Citing Heavy Workload

1 month ago talkbio0Tagged Angioedemas, Hereditary, constraints, Deferred, Drug Approval, KalVista, on-demand, Oral cavity, PDUFA, Resources, Sebetralstat, United States Food and Drug Administration

KalVista Pharmaceuticals; sebetralstat; FDA delay; hereditary angioedema; resource constraints; PDUFA date; drug approval; oral on-demand treatment

Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

1 year ago talkbio0Tagged Angioedemas, Hereditary, Collaboration, Editas Medicine, KalVista, Myers, Partnership, preclinical program, squibb, T cell therapy

Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.